A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Inclusion Criteria: * Patient must have histologically proven adenocarcinoma of the prostate gland. * Patient must have evidence of progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or lung metastases) within 6 weeks prior to participation in the study. * Patients must not have an elevated PSA level as the only evidence of disease. While castrated, the patients should have rising PSA on two consecutive measurements at least 1 week apart. The confirmatory PSA must be obtained within 1 week prior to study registration and should be \>10ng/ml. * Patients with bone metastases only (i.e., lacking soft-tissue disease) must have a PSA level of \> 10 ng/ml. Patients with soft tissue metastases and /or visceral disease must have either measurable disease or a PSA level of \> 10 ng/ml. * Radiological evidence of hydronephrosis will not by itself constitute evidence of metastatic disease. * Patients must have had prior treatment with bilateral orchiectomy or other primary hormonal therapy (e.g., estrogen therapy, LHRH analog + flutamide, etc.) with evidence of treatment failure. NOTE: Patients who have not undergone bilateral orchiectomy must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) while receiving this protocol therapy. * For patients previously treated with flutamide (Eulexin), nilutamide (Nilandron), or bicalutamide (Casodex): Patients must have discontinued flutamide or nilutamide \< 4 weeks and for bicalutamide 6 weeks prior to registration. * Patients should not have prior exposure to anthracyclines or estramustine phosphate. * Patients must not have had prior radiotherapy \< 4 weeks prior to this protocol treatment. * Patients must not have previously received Strontium 89, Samarium 153, or other radioisotope therapies. * Patients must have recovered from all toxicities due to prior treatment for prostate cancer prior to receiving this protocol treatment. * Patients must have adequate bone marrow function: (WBC \> 4000/ mm3, granulocytes \> 2000/ mm3, platelet count \> 100,000/mm3, and Hemoglobin \> 8.0 g/dl \< 4 weeks prior to participate in this study. * Patients must have the following chemistry values \< 4 weeks prior to participate in this study: * Bilirubin \< 1.5 mg/dl * Transaminases (SGOT and/or SGPT) \< 5 x institutional upper limit of normal (ULN) * Creatinine \< 2.0 mg/d. or creatinine clearance \> 50 ml/min * Alkaline phosphatase £ 5 x ULN * Patients must have no active angina pectoris, or known heart disease of New York Heart Association Class III-IV. Patients must not have a history of myocardial infarction \< 6 months prior to the study participation. * Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for the specific cancer. * No serious concurrent medical illness or active infection should be present which would jeopardize the ability of the patient to receive the chemotherapy outlined in this protocol with reasonable safety. * Sexually active patients must use an accepted and effective method of contraception while receiving protocol treatment. * Patients must have a Karnofsky Performance Scale (KPS) score over 50. (Equaling ECOG Performance Scale of 0, 1, or 2). * Age \> 18 years. * Patient must have failed the Taxotere treatment. Exclusion Criteria: